{"text": ["Roche", "Tecentriq", "Phase", "III", "Combo", "Study", "Meets", "Primary", "Endpoint"], "created_at": "2018-03-20 23:07:12"}
{"text": ["Roche", "Tecentriq", "Phase", "III", "Combo", "Study", "Meets", "Primary", "Endpoint"], "created_at": "2018-03-20 23:07:12"}
{"text": ["CVS", "appoints", "former", "Eli", "Lilly", "CFO", "as", "president", "of", "PBM", "business"], "created_at": "2018-03-20 21:16:52"}
{"text": ["Understanding", "Nektar", "Therapeutics\u2019", "Top-Line", "Performance"], "created_at": "2018-03-20 17:07:18"}
{"text": ["CVS", "to", "Hire", "Former", "Eli", "Lilly", "CFO", "to", "Run", "Pharmacy", "Benefit", "Business"], "created_at": "2018-03-20 14:02:21"}
{"text": ["3", "High-Quality", "Dividend-Payers", "Selling", "at", "a", "Discount"], "created_at": "2018-03-20 10:00:00"}
